Aviado · Research
Longevity Daily
Monday, June 8, 2026
Listen
Today's Brief
Today's lead: GLP-1 receptor agonists like semaglutide significantly outperform metformin at reducing dementia risk in type 2 diabetics — a finding that should reshape how clinicians and patients think about this drug class. In the lab, an old antidepressant called mianserin extended mouse lifespan by 17.5% by correcting calcium dysregulation, pointing to a new lever in aging biology. We also cover a rare genetic variant that adds seven years of healthy life, the FDA's milestone support for a canine longevity drug and what it signals for humans, and whether Neuriva actually earns its brain-health claims.
10 stories1 peer-reviewed2 trials
Cognitive Health & Neuroprotection
GLP-1 Drugs Outperform Metformin at Reducing Dementia Risk -- by a Meaningful Margin
A large comparative analysis finds GLP-1 receptor agonists -- the class that includes semaglutide (Ozempic/Wegovy) and liraglutide -- significantly reduce overall dementia risk compared to metformin in patients with type 2 diabetes, with particularly strong protection against Alzheimer's disease and non-vascular dementias. This builds on earlier signals that GLP-1s reduce neuroinflammation and improve cerebral blood flow, suggesting their benefits extend well beyond blood sugar control. The finding matters beyond the diabetic population: it raises serious questions about whether GLP-1 drugs should be considered a first-line option for older adults at elevated dementia risk. If you or a family member with T2DM is choosing between these medications, this is worth bringing to your next appointment.
Read more →Supplements & Compounds
Vitamin K2 as MK-7 Lowers Blood Pressure and Protects Arteries in Menopausal Women
A new analysis of the MenaQ7 trial finds that vitamin K2 supplementation as MK-7 significantly counters the vascular damage that accelerates after menopause, including measurable improvements in blood pressure and arterial flexibility. The mechanism is well-established: MK-7 activates matrix Gla protein (MGP), which prevents calcium from depositing in artery walls -- a process that surges as estrogen declines. If you are a woman over 50 and not already supplementing with K2, this is one of the more evidence-backed cardiovascular interventions in the space.
Read more →Neuriva: What the Science Actually Shows About America's Best-Selling Brain Supplement
Neuriva markets itself as supporting five cognitive functions -- memory, accuracy, learning, focus, and concentration -- but a Pharmacy Times review finds the clinical evidence behind its key ingredients is thin. Coffee cherry extract and phosphatidylserine each have limited peer-reviewed support for meaningful cognitive improvement, and none of the branded claims have been evaluated by the FDA. If you're spending $30+ per month on Neuriva, this review is worth reading before your next purchase.
Read more →Long-Term Metformin Use Depletes Vitamin B12 -- and That's a Nerve Damage Risk Worth Knowing
Metformin is one of the most prescribed drugs in the world -- and a top longevity candidate -- but long-term use impairs B12 absorption in the gut, and deficiency can quietly progress to peripheral neuropathy before symptoms appear. The risk is dose- and duration-dependent, making it especially relevant for anyone who has taken metformin for years as a diabetes or anti-aging intervention. The practical fix is straightforward: regular B12 monitoring and supplementation, but many patients and prescribers aren't doing it.
Read more →Research & Papers
An Old Antidepressant Extended Mouse Lifespan by 17% -- Calcium May Be the Hidden Clock of Aging
Published in Nature Communications, a new study shows mianserin, a decades-old tetracyclic antidepressant, extended median lifespan in naturally aging mice by approximately 17.5% -- even when treatment began at an age equivalent to human mid-60s. The mechanism points to a surprising culprit: chronic calcium dysregulation in aging cells triggers a cascade of DNA damage, senescent cell buildup, and the inflammatory SASP secretions that drive tissue decline across the body. This is a mouse study and mianserin carries known side effects, but calcium homeostasis now emerges as a credible, largely unexplored target in longevity research.
Read more →How Reproduction Resets the Aging Clock -- And What It Means for Rejuvenation Therapies
Every time life begins, two aged cells fuse to produce a completely young organism -- resetting the biological clock to zero through processes science is only beginning to map. Researchers have now identified regulatory systems that shield the germline from aging and orchestrate a full cellular reset during embryonic development, discoveries that are directly inspiring partial reprogramming therapies aimed at restoring youthful function to adult tissues. Understanding how nature already solves the aging problem at conception may be the key to replicating those mechanisms therapeutically -- without converting cells back to stem cells.
Read more →Lifestyle & Nutrition
Your Cells Have a Different Age Than Your Passport -- Here's What That Actually Means
Epigenetic clocks -- which measure DNA methylation patterns to estimate biological age -- are moving from research labs into consumer health platforms, and this explainer is one of the clearest available primers on what you're actually measuring. The piece references the first randomized controlled trial to demonstrate a meaningful biological age reversal: participants in a structured lifestyle intervention scored a mean of 2.04 years younger at program's end. If you're considering biological age testing, this is a solid guide to interpreting results and identifying the interventions that actually move the needle.
Read more →Industry & Policy
FDA Backs First-Ever Drug for Canine Lifespan Extension -- and the Implications for Human Longevity Are Real
The FDA has granted a 'Reasonable Expectation of Effectiveness' designation to Loyal's LOY-002, a drug designed to extend the healthy lifespan of senior dogs -- the first time the agency has ever validated an aging-extension indication for any species. As Loyal's CEO explains, an aging drug slows the rate of biological decline rather than treating disease at end-of-life, creating more healthy years earlier in the curve. Dogs and humans share roughly 65% of disease-associated genes and face nearly identical aging mechanisms, making this arguably the most translatable preclinical model for human longevity medicine now in active trials.
Read more →FDA-Cleared Vibration Device That Slows Bone Loss Launches Nationwide
Osteoboost, a wearable device that delivers calibrated vibration to the hips, is now available nationwide following FDA clearance and clinical trial data showing significant reductions in bone density and strength loss compared to controls, with no serious adverse events. Bone loss is one of the most undermanaged longevity risks -- osteoporosis affects one in three women and one in five men over 50 and sharply raises fracture and mortality risk. For adults looking for a drug-free complement or alternative to bisphosphonates, this is a development worth discussing with your physician.
Read more →